Name | No. | For Patients with | Purpose |
---|---|---|---|
Exosomes in TNBC | 22-21 | Early or metastatic triple negative breast cancer (TNBC) |
The main purpose of this study is to profile exosomes isolated from the plasma of women diagnosed with TNBC during routine treatment and follow up in the oncology clinic using Nanoparticle tracking analysis (NTA) and Raman/infra-red spectroscopy. |
DSSG Group: Breast
UCARE
Name | No. | For Patients with | Purpose |
---|---|---|---|
UCARE | 24-21 | Female patients diagnosed with stage I-III breast cancer. |
The main purpose of the study is to evaluate pathways for identifying, managing, and overcoming side effects of cancer therapies that can negatively impact quality-of-life and overall outcomes for women during and after cancer treatment. |
EXPERT
Name | No. | For Patients with | Purpose |
---|---|---|---|
EXPERT | 19-03 | Patients with luminal A early breast cancer who had breast conserving surgery and endocrine therapy |
The purpose of this study is to see whether a genomic test (looking at specific genes) of breast cancer tissue can be used to select women who can safely avoid radiation therapy because they have a low risk of the cancer coming back. |
EPIK-B5
Name | No. | For Patients with | Purpose |
---|---|---|---|
EPIK-B5 | 21-32 | HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation who progressed or relapsed on or after treatment with an AI plus a CDK4/6 inhibitor. |
The purpose of this study is to obtain more comprehensive data on the efficacy and safety of alpelisib (BYL719) in combination with fulvestrant compared with placebo plus fulvestrant in men or postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation who progressed or relapsed on or after treatment with an AI plus a CDK4/6 inhibitor. |
Proteomics / Molecular Breast
Name | No. | For Patients with | Purpose |
---|---|---|---|
Proteomics / Molecular Breast | 09-07 | Breast cancer |
The purpose of this trial is to examine the function of different genes and proteins, previously identified to be of interest, and identify new ones, as well as the means by which they interact and differ between cancer cells. |